)and90%of
the time for the cell-to-cell spread assay(n= 30 compounds)
(5)Tremblay,S.;Dansereau,N.;Balsitis,S.;Franti,M.;Lamorte,L.
Development of a high-throughput human cytomegalovirus quantita-
tive PCRcell-based assay. J. Virol.Methods 2014,195,67−71.
(6)Fader,L.;Parisien,M.;Thibeault,C.;Morency,L.;Duplessis,M.;
James,C.;Morin,S.;Gillard,J.Preparationofphenylacetylaminophe-
nylthiazolecarboxamide derivatives and analogs for use as cytomega-
lovirus inhibitors. PCTInt. Appl., WO 2014/70979.
(7) Fader, L.; Bilodeau, F.; Poirier, M.; Parisien, M.; Kuhn, C.;
Thibeault, C.; Trinh, T. Preparation of phenylimidazolylphenylth-
iazolecarboxamide derivatives and analogs for use as cytomegalovirus
inhibitors. PCT Int.Appl., WO2014/70978.
(8)Bloom,J.D.;DiGrandi,M.J.;Dushin,R.G.;Curran,K.J.;Ross,
A.A.;Norton,E.B.;Terefenko,E.;Jones,T.R.;Feld,B.;Lang,S.A.
Thiourea inhibitors of herpes viruses. Part 1: Bis-(aryl)thiourea
inhibitors of CMV.Bioorg. Med.Chem. Lett.2003, 13, 2929−2932.
(9)Jones,T.R.;Lee,S.-W.;Johann,S.V.;Razinkov,V.;Visalli,R.J.;
Feld, B.; Bloom, J. D.; O’Connell, J. Specific inhibition of human
cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea
small molecule. J. Virology 2004,78,1289−1300.
